| Identification | Back Directory | [Name]
7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- | [CAS]
1858206-58-2 | [Synonyms]
TG-1701
Edralbrutinib
(R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one
4-Amino-3-[4-(2,6-difluoro-phenoxy)-phenyl]-1-[1-(1-oxo-but-2-ynyl)-pyrrolidin-3-yl]-1,6-dihydro-pyrrolo[2,3-d]pyridazin-7-one
7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- | [Molecular Formula]
C26H21F2N5O3 | [MOL File]
1858206-58-2.mol | [Molecular Weight]
489.47 |
| Hazard Information | Back Directory | [Uses]
Edralbrutinib (TG-1701) is a potent BTK inhibitor[1]. | [References]
[1] JIANGSU HENGRUI MEDICINE CO, et al. Pharmaceutically acceptable salt and crystal form of pyrrolo[2,3-d]pyridazin-7-one derivative and preparation method of medicinal salt and crystal form. WO2018210296A1. |
|
|